Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

peptidase/umor

Veza se sprema u međuspremnik
9 rezultati

Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor

Rhinorrhea, cough and fatigue in patients taking sitagliptin.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. We report fifteen sitagliptin intolerant patients who developed anterior and posterior rhinorrhea, cough, dyspnea, and fatigue. Symptoms typically
Alterations of the expression of some peptidases in the pituitary gland of a fatigued rat model were identified. Rats were kept in a cage filled with water to a height of 1.5 cm to disturb deep sleep. After 24-h sleep disturbance, expression of neutral endopeptidase 24.11 (neprilysin) mRNA was

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as "gliptins". They are approved for use as oral glucose-lowering agents, although they have no proven impact on morbidity or mortality. Their glucose-lowering effect is limited and their long-term risks are

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND Drug resistance continues to be a major challenge in the treatment of HIV-1 infection. Virtually all currently available antiretroviral medications inhibit the viral reverse transcriptase or protease. Enfuvirtide is the first fusion inhibitor approved by the US Food and Drug

Probable linagliptin-induced liver toxicity: a case report.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE Unlike other dipeptidyl peptidase 4 (DPP-4) inhibitors, the excretion of linagliptin is mainly through a biliary route. Despite this fact, liver injury with linagliptin has thus far not been reported in the literature. However, this report describes the first case of probable
We present a case of unknown fever and abnormal liver functions which developed during the course of pain management for herpes zoster with repeated epidural blocks with 0.5% lidocaine 10 ml. The patient was a 67 year old woman. At her first admission to dermatology, there were no abnormal findings

Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
PT-100 upregulates cytokine expression competitively inhibiting the dipeptidyl peptidase activity of fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP-IV). This dose-escalation study was conducted to evaluate the safety of PT-100 in patients receiving myelosuppressive chemotherapy

Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND The number of elderly type 2 diabetes mellitus (T2DM) patients in Japan is increasing continuously. Hypoglycemia is a significant issue in their treatment. However, the actual situation and related details of their hypoglycemia remain unclear. In order to elucidate them, the Japan
Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge